[{"id":"cc2513e1-1118-413d-afc7-11dae0bbd470","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743298","created_at":"2021-01-18T18:20:06.213Z","updated_at":"2025-02-25T16:31:40.505Z","phase":"Phase 1b","brief_title":"Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma","source_id_and_acronym":"NCT03743298","lead_sponsor":"Aivita Biomedical, Inc.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AV-MEL-1"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-04-10"}]